Eli Lilly

New clinical trial data released by Eli Lilly on Wednesday has provided the most promising results of any potential Alzheimer’s disease treatment yet. In a randomized, double-blinded, controlled phase III trial, the experimental drug donanemab significantly slowed cognitive decline in patients compared to placebo, with nearly half of those on the drug experiencing no decline at all a year later. The findings will likely pave the way for approval by the Food and Drug Administration, though the drug appears to carry a risk…

Twitter owner Elon Musk has tried foisting checkmarks upon celebrity accounts in a bid to popularize his paid-for verification scheme. In this way, Musk and Twitter may have been going a little too fast with its push for Twitter Blue subscriptions, and it may have pissed off the indomitable House of Mouse in the process. Twitter Verification is a Hot MessOver the weekend, Twitter offered a gold checkmark to the account titled “Disney Junior UK.” Other Disney-brand accounts like the regular “Disney Junior” and “Disney”…

Weight-loss drugmakers are lobbying Congress to grant them access to a monster payday for their blockbuster treatments: Medicare coverage. New drugs to treat diabetes and obesity are helping people shed pounds and generating huge sales for Novo Nordisk AS and Eli Lilly & Co. But they cost hundreds of dollars a month or more and Medicare doesn’t cover them to treat obesity. The law governing Medicare’s prescription-drug benefit excludes weight drugs. If that changed, demand from the 65 million…

Technology companies including Google parent Alphabet Inc. and Amazon . com Inc. as well as stalwarts from the food, pharmaceutical and energy sectors, highlight a busy earnings week amid concerns about the U.S. economy. The coming reports will provide clues to investors about how companies fared in the first quarter of 2023 as the recent banking crisis, continuing layoffs in sectors such as technology, and inflation weighed on the economy. Technology companies including Google parent…

The drug Mounjaro helped a typical person with obesity who weighed 230 pounds lose up to 50 pounds during a test period of nearly 17 months. No anti-obesity drug has ever safely made such a difference. In the coming months, it is widely expected to get the go-ahead from U.S. health regulators to be prescribed for losing weight and keeping it off, and some patients are already using it unapproved for that purpose. The advance of Mounjaro, which is already on the market to treat Type 2 diabetes, has excited…

French drugmaker Sanofi SA said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big pharmaceutical companies facing pressure to reduce the cost of diabetes treatments.Sanofi plans to take a 78% list-price reduction on Lantus, the company’s most widely used insulin in the U.S., and a 70% cut on its Apidra product starting in January 2024, the company said Thursday.  Sanofi also said it would cap a Lantus patient’s monthly out-of-pocket cost…

Sen. Bernie Sander’s new bill will cap drug prices to what Eli Lilly’s Humalog cost when it was first released in 1996.Photo: Spencer Platt (Getty Images)On Thursday, Vermont Sen. Bernie Sanders and a gaggle of Democrats introduced a new bill that would cap insulin drug prices to just $20 per vial no matter which company is making it.The bill, called the Insulin for All Act of 2023, caps the price at what the major pharmaceutical company Eli Lilly originally setfor a month’s supply of its insulin treatment Humalog back…

An experimental drug from Eli Lilly LLY 0.61% & Co. failed to prevent memory loss in a study of healthy older people with a high risk of developing clinical Alzheimer’s disease in one of the first studies aimed at stopping symptoms before they start.  The drug was no better than a placebo over about 4½ years of treatment at slowing patients’ decline in areas including memory and the ability to plan and complete tasks, Lilly said…

Image: Daniel Beckemeier (Shutterstock)An Insulin drugmaker announced it is making its drug more affordable for some diabetics and is capping the out-of-pocket cost at $35 per month. Eli Lilly is making Insulin immediately available to seniors on Medicare. It’s welcome news to the many Americans who rely on insulin, as the cost of care has soared in recent years.The company is automatically applying the price cap for Insulin to seniors who have private insurance and those without can sign up for Eli Lilly’s copay…

Eli Lilly & Co., facing pressure to curb diabetes-treatment costs, will cut the list prices for its most commonly prescribed insulin products by 70% and take other steps to make it easier for patients to afford the drugs.  The Indianapolis-based company said Wednesday the 70% price cuts will take effect in the fourth quarter for Humalog and Humulin, its two biggest-selling insulin products.  The company also said that on May 1 it would…